Legacy in Cardiovascular Risk Factors Control: From Theory to Future Therapeutic Strategies?

In medicine, a legacy effect is defined as the sustained beneficial effect of a given treatment on disease outcomes, even after cessation of the intervention. Initially described in optimized control of diabetes, it was also observed in clinical trials exploring intensification strategies for other...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lucie Pothen, Jean-Luc Balligand
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	metabolic memory legacy effect ROS diabetes hypertension angiotensin II Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/0956d50ae29a4feca4d723245d92988d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0956d50ae29a4feca4d723245d92988d
record_format	dspace
spelling	oai:doaj.org-article:0956d50ae29a4feca4d723245d92988d2021-11-25T16:29:49ZLegacy in Cardiovascular Risk Factors Control: From Theory to Future Therapeutic Strategies?10.3390/antiox101118492076-3921https://doaj.org/article/0956d50ae29a4feca4d723245d92988d2021-11-01T00:00:00Zhttps://www.mdpi.com/2076-3921/10/11/1849https://doaj.org/toc/2076-3921In medicine, a legacy effect is defined as the sustained beneficial effect of a given treatment on disease outcomes, even after cessation of the intervention. Initially described in optimized control of diabetes, it was also observed in clinical trials exploring intensification strategies for other cardiovascular risk factors, such as hypertension or hypercholesterolemia. Mechanisms of legacy were particularly deciphered in diabetes, leading to the concept of metabolic memory. In a more discreet manner, other memory phenomena were also described in preclinical studies that demonstrated long-lasting deleterious effects of lipids or angiotensin II on vascular wall components. Interestingly, epigenetic changes and reactive oxygen species (ROS) appear to be common features of “memory” of the vascular wall.Lucie PothenJean-Luc BalligandMDPI AGarticlemetabolic memorylegacy effectROSdiabeteshypertensionangiotensin IITherapeutics. PharmacologyRM1-950ENAntioxidants, Vol 10, Iss 1849, p 1849 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	metabolic memory legacy effect ROS diabetes hypertension angiotensin II Therapeutics. Pharmacology RM1-950
spellingShingle	metabolic memory legacy effect ROS diabetes hypertension angiotensin II Therapeutics. Pharmacology RM1-950 Lucie Pothen Jean-Luc Balligand Legacy in Cardiovascular Risk Factors Control: From Theory to Future Therapeutic Strategies?
description	In medicine, a legacy effect is defined as the sustained beneficial effect of a given treatment on disease outcomes, even after cessation of the intervention. Initially described in optimized control of diabetes, it was also observed in clinical trials exploring intensification strategies for other cardiovascular risk factors, such as hypertension or hypercholesterolemia. Mechanisms of legacy were particularly deciphered in diabetes, leading to the concept of metabolic memory. In a more discreet manner, other memory phenomena were also described in preclinical studies that demonstrated long-lasting deleterious effects of lipids or angiotensin II on vascular wall components. Interestingly, epigenetic changes and reactive oxygen species (ROS) appear to be common features of “memory” of the vascular wall.
format	article
author	Lucie Pothen Jean-Luc Balligand
author_facet	Lucie Pothen Jean-Luc Balligand
author_sort	Lucie Pothen
title	Legacy in Cardiovascular Risk Factors Control: From Theory to Future Therapeutic Strategies?
title_short	Legacy in Cardiovascular Risk Factors Control: From Theory to Future Therapeutic Strategies?
title_full	Legacy in Cardiovascular Risk Factors Control: From Theory to Future Therapeutic Strategies?
title_fullStr	Legacy in Cardiovascular Risk Factors Control: From Theory to Future Therapeutic Strategies?
title_full_unstemmed	Legacy in Cardiovascular Risk Factors Control: From Theory to Future Therapeutic Strategies?
title_sort	legacy in cardiovascular risk factors control: from theory to future therapeutic strategies?
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/0956d50ae29a4feca4d723245d92988d
work_keys_str_mv	AT luciepothen legacyincardiovascularriskfactorscontrolfromtheorytofuturetherapeuticstrategies AT jeanlucballigand legacyincardiovascularriskfactorscontrolfromtheorytofuturetherapeuticstrategies
_version_	1718413118055383040

Legacy in Cardiovascular Risk Factors Control: From Theory to Future Therapeutic Strategies?

Ejemplares similares